ANI PHARMACEUTICALS INC
ANIPNASDAQTrading Snapshot
- Day Range
- $72.40 – $73.29
- 52-Week Range
- $69.58 – $97.00
- Volume
- $4.11B
- Avg Volume
- $3.11B
- Shares Outstanding
- 22.7M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $883M
- Last Q Revenue
- $266M
- P/E Ratio
- 15.0
- P/S Ratio
- 1.7x
- EPS (TTM)
- $5.00
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.2%
Why Investors Own ANIP
- ✓High-growth profile — revenue up +34.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 42% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ANI PHARMACEUTICALS INC
ANIP
StockOtter · stockotter.spaceAbout ANI PHARMACEUTICALS INC
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its A
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two bus